Valneva SE

  Valneva Announces Successful Outcome of its AGM and the Appointment of Pfizer’s Former Vaccine R&D Head to its Supervisory Board

21 Jun 2023 11:15:00 By Nasdaq GlobeNewswire

Valneva Announces Publication of its Chikungunya Vaccine Candidate Phase 3 Data in The Lancet

13 Jun 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights: May 31, 2023

07 Jun 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva to Present and Hold Investor Meetings at Upcoming Conferences in June

31 May 2023 00:15:00 By Nasdaq GlobeNewswire

Valneva Announces the Availability of Documentation for its Shareholder Meeting

31 May 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Files for Chikungunya Vaccine Authorization with Health Canada

30 May 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - April 30, 2023

04 May 2023 11:00:00 By Nasdaq GlobeNewswire

Valneva Reports First Quarter 2023 Financial Results and Provides Corporate Updates

04 May 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - March 31, 2023

06 Apr 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Announces Filing of 2022 Universal Registration Document and US Form 20-F

31 Mar 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva to Present on its Chikungunya Vaccine Candidate and Host a Roundtable at the 23rd World Vaccine Congress in Washington D.C.

30 Mar 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2022 Results and Provides Corporate Updates

23 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

VALNEVA - Declaration of shares and voting rights - February 28, 2023

06 Mar 2023 01:00:00 By Nasdaq GlobeNewswire

Valneva Provides Clinical and Regulatory Updates for its COVID-19 Vaccine VLA2001

02 Mar 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva to Present at the Cowen 43rd Annual Healthcare Conference

01 Mar 2023 10:45:00 By Nasdaq GlobeNewswire

FDA Accepts Valneva’s Chikungunya Vaccine License Application for Priority Review

20 Feb 2023 00:00:00 By Nasdaq GlobeNewswire

Pfizer and Valneva Issue Update on Phase 3 Clinical Trial Evaluating Lyme Disease Vaccine Candidate VLA15

17 Feb 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Reports Full Year 2022 Revenue and Cash, Provides First 2023 Guidance

16 Feb 2023 00:00:00 By Nasdaq GlobeNewswire

Valneva Completes Enrollment for Adolescent Phase 3 Trial of Single-Shot Chikungunya Vaccine Candidate

14 Feb 2023 00:00:00 By Nasdaq GlobeNewswire

VALNEVA Declaration of shares and voting rights - January 31, 2023

03 Feb 2023 11:00:00 By Nasdaq GlobeNewswire